Hims & Hers Health shares have fallen 7.7% since its second-quarter earnings report, underperforming the S&P 500. The company reported an adjusted loss per share of 10 cents, wider than the expected loss of 7 cents, while revenue rose 38.2% to $753.2 million, beating estimates by 9.1%. Gross margin contracted to 63.8% from 76.4% a year earlier, and operating loss totaled $97.2 million versus a year-ago profit. For the third quarter, Hims & Hers projects revenue of $880 million to $900 million, and for the full year it raised its outlook to $3.1 billion to $3.3 billion, up from a prior range of $2.8 billion to $3 billion. Since the earnings release, consensus estimates have shifted downward by 27.35%, and the stock holds a Zacks Rank #3 (Hold).
Hims Hers Health IncQ2 adjusted loss per share of 10 cents was wider than the expected 7-cent loss, with gross margin contracting to 63.8% from 76.4% and an operating loss of $97.2 million.
10X Genomics Inc